You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 14, 2024

Investigational Drug Information for AG-881


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for AG-881?

AG-881 is an investigational drug.

There have been 10 clinical trials for AG-881. The most recent clinical trial was a Phase 1 trial, which was initiated on January 5th 2020.

The most common disease conditions in clinical trials are Glioma, Cholangiocarcinoma, and Myelodysplastic Syndromes. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., Institut de Recherches Internationales Servier, and Merck Sharp & Dohme LLC.

There are seven US patents protecting this investigational drug and one hundred and eleven international patents.

Recent Clinical Trials for AG-881
TitleSponsorPhase
A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic FunctionInstitut de Recherches Internationales ServierPhase 1
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant AstrocytomasMerck Sharp & Dohme LLCPhase 1
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant AstrocytomasInstitut de Recherches Internationales ServierPhase 1

See all AG-881 clinical trials

Clinical Trial Summary for AG-881

Top disease conditions for AG-881
Top clinical trial sponsors for AG-881

See all AG-881 clinical trials

US Patents for AG-881

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-881 ⤷  Sign Up Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
AG-881 ⤷  Sign Up Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
AG-881 ⤷  Sign Up Methods of treating brain tumors using combination therapy Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
AG-881 ⤷  Sign Up ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AG-881

Drugname Country Document Number Estimated Expiration Related US Patent
AG-881 Argentina AR096902 2033-07-11 ⤷  Sign Up
AG-881 Australia AU2014289744 2033-07-11 ⤷  Sign Up
AG-881 Australia AU2019201179 2033-07-11 ⤷  Sign Up
AG-881 Brazil BR112016000561 2033-07-11 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.